Osteocalcin Alleviates Nonalcoholic Fatty Liver Disease in Mice through GPRC6A

Figure 1

The effects of osteocalcin and GPRC6ALKO on body weight and fasting blood glucose. (a) Verification of GPRC6ALKO through western blotting; (b) body weight (g); (c) fasting blood glucose levels (mmol/L). GPRC6ALKO mice or WT mice were fed with HFD diet and treated daily with 30 ng/g/day uncarboxylated osteocalcin or saline solution. Data were expressed as the mean ± SEM and were analyzed by independent-samples T-test. , the WT : HFD + OCN group compared with the WT : HFD + NS group. GPRC6ALKO, liver-specific conditional GPRC6A knockout; WT, wild-type; NS, saline solution; HFD, high-fat diet; OCN, osteocalcin. The effects of osteocalcin and GPRC6ALKO on glucose tolerance and insulin sensitivity.

(a)

(b)

(c)